(Finance) – The Board of Directors of Svas Biosana examined and approved the consolidated financial statements and the draft financial statements at 31 December 2021 to be submitted to the Ordinary Shareholders’ Meeting to be held on 16 May 2022 in first call and, if necessary, on 17 May in second call.
“The 2021 financial year was a very important year for our company characterized by development and growth which involved all corporate aspects, ultimately culminating in the listing of SVAS on the stock exchange – he comments Umberto Perillo, Chief Executive Officer of Svas Biosana -. Despite the complex period, strongly influenced by the persistence of the Covid-19 pandemic but even more by the increase in raw material costs, the Group has consolidated and expanded its market position, confirming itself among the major operators in Italy and the first operator in Balkans in this area. For 2022, we expect a further significant development of activitiesboth commercial and industrial, thanks also to the financial deposits deriving from the listing on Euronext Growth Milan ”.
The year 2021 was a positive year for the Group that achieved Consolidated revenues for 81.1 million Euros (with an increase of 6.6% compared to 2020) and a Consolidated EBITDA of 10.6 million Euros (+ 11.2% on 2020).
The Board of Directors resolved to propose to the Shareholders’ Meeting to allocate the profit for the year of Euro 1,069,306: Euro 53,465 to the legal reserve; Euro 1,015,841 to the extraordinary reserve.